e-therapeutics announces completion of £28.90 million fundraise

London, UK, 3 July 2024 - e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased to announce that it has completed its £28.90 million fundraise by way of a subscription by funds managed by M&G Investment Management Limited and Richard Griffiths and his controlled undertakings, both existing shareholders of the Company. The Subscription by M&G was conditional upon clearance under the National Security and Investment Act 2021, which is now complete.

The proceeds from the fundraise will be used to advance multiple GalOmic™ pipeline assets towards the clinic and initiate clinical trials on one program. The Company also plans to use the proceeds to keep its early pipeline well populated and accelerate development and integration of cutting-edge AI systems into its HepNet™ computational platform. Additionally, the Company will explore the option of listing on NASDAQ in due course.

Following the allotment and issue of shares, the Company has 777,002,154 ordinary shares of 0.1 pence each in issue each with voting rights in the Company.